Atrial Fibrillation in Hypertrophic Cardiomyopathy

Игнатенко, Г. А.; Тарадин, Г. Г.; Ватутин, Н. Т.; Калуга, А. А.; Костямин, Ю. Д.

doi:10.20514/2226-6704-2021-11-3-173-185

Cited by 3 publications

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Фибрилляция предсердий (ФП) при ГКМП возникает у 14-28 % пациентов, плохо переносится, трудно поддается лечению [28], связана с повышенным риском тромбоэмболических осложнений (появление ФП увеличивает риск ишемического инсульта в 8 (!) раз), СН, ВСС и смерти от всех причин [29,30]. ГКМП может сочетаться с другой сердечно-сосудистой патологией (ишемической болезнью сердца, АГ, сахарным диабетом) [31], особенно с увеличением возраста пациентов [32].…”

Section: краткая характеристика гипертрофической кардиомиопатии: определение клиника методы диагностики осложнения лечениеunclassified

“…Для выявления эмболических событий, прежде всего, мозговых сосудов, в том числе бессимптомных, показано выполнение МРТ или КТ головного мозга. Тромбоэмболии развиваются у 2-9 % больных ГКМП и в отсутствие ИЭ [7], составляя от 2 до 11 % в структуре причин смерти больных с ГКМП [27], а возникновение ФП у пациентов с ГКМП связано со значительным риском кардиоэмболического инсульта [20,[28][29][30][31]. При ИЭ на фоне ГКМП такое осложнение может возникнуть при синусовом ритме [11].…”

Section: частота возникновения гемодинамические условия и локализация клапанного поражения при инфекционном эндокардите на фоне гипертрофunclassified

See 1 more Smart Citation

Infective Endocarditis in Patients with Hypertrophic Cardiomyopathy

Пономарева

Игнатенко

Тарадин

2021

Arhivʺ vnutrennej mediciny

Self Cite

View full text Add to dashboard Cite

A literature review is presented, reflecting the incidence, etiology, hemodynamics, localization, clinical manifestations, outcomes and treatment of infective endocarditis (IE) in patients with hypertrophic cardiomyopathy (HCM). Despite the relative rarity of IE in patients with HCM, the combination of these pathologies is characterized by mutual aggravation and poor prognosis. The addition of IE increases the risk of death in patients with obstructive HCM, deteriorating circulatory disorders, increasing the likelihood of uncontrolled sepsis and embolism. Conservative treatment of IE in patients with HCM does not differ from that without HCM. Interdisciplinary interaction is needed in the management of patients with IE against the background of HCM in determining the indications for cardiac surgery and choosing the optimal method. Antibacterial prophylaxis of IE before invasive medical manipulations in patients with HCM is not recommended by the current consensus documents, however, the decision for each patient should be made individually, with a mandatory assessment of the risk of IE, the severity of hemodynamic disorders and prognosis.

show abstract

Infective Endocarditis in Patients with Hypertrophic Cardiomyopathy

Пономарева

Игнатенко

Тарадин

2021

Arhivʺ vnutrennej mediciny

Self Cite

View full text Add to dashboard Cite

show abstract

Determining The Risk of Atrial Fibrillation Paroxysm in Patients With Chronic Heart Failure With Intact and Reduced Ejection Fraction

Zakharov,

Chomakhidze,

Kopylov

et al. 2024

Kardiologiia

View full text Add to dashboard Cite

Aim. To determine predictors for the development of atrial fibrillation (AF) in patients with chronic heart failure (CHF) with preserved and reduced ejection fraction by echocardiography (EchoCG) according to an extended protocol with determination of diastolic function and left atrial global strain.Material and methods. Data of 168 patients with stage I–III CHF without a history of AF were analyzed. All patients underwent echocardiography according to an extended protocol with the determination of diastolic dysfunction (DD), left atrial ejection fraction (LA EF), and left atrial global strain (LA GS). Tissue Doppler imaging (TDI) was used to evaluate the early (E) and late (A) LV filling velocity and the early (E') and late (A') diastolic mitral annular velocity. In all patients, Holter ECG monitoring (HM ECG) of heart rhythm was performed for 3 days, and ECG monitoring with telemedicine technologies was performed for 7 days, 3 times a day for 3 minutes. The follow-up period was 3 months or until an AF episode.Results. During the study, paroxysmal AF (pAF) was detected in 41 (24.4%) patients using various methods of heart rhythm monitoring. Complaints of palpitations were noted for 10 (24.4%) patients during pAF, which was recorded using a CardioQVARK® device, HM ECG or a 12-lead ECG. In 5 (12.2%) patients, daily ECG monitoring revealed pAF without associated complaints. HM ECG detected 8, 2, 4 (19.5%, 4.8%, and 9.7%) cases during 24, 48 and 72 hours, respectively; a single-channel CardioQVARK® detected 30 (73.2%) cases when used 3 times a day for 7 days. These results showed that AF frequently develops in CHF without accompanying symptoms. The method for detecting pAF with CardioQVARK® showed good results: it was twice more effective than HM ECG and three times more effective than 12-lead ECG. Also, according to ultrasound data, significant changes in the following parameters were noted in patients with AF: LA EF <36% (OR 1.04, 95% CI: 1.02-1.08), p=0.003; LA GS <9.9% (OR 1.16, 95% CI: 1.02-1.38), p<0.001; TDI E med <5.7 cm/s (OR 0.97, 95% CI: 0.94-1.00), p=0.026. Grade 2 DD did not show statistically significant results (OR 1.1, 95% CI: 0.7–1.5, p=0.54). However, it was detected more frequently in patients with AF, in 34% of cases, compared to 29% of cases in patients without AF, which requires further study on a larger patient sample.Conclusion. Patients with CHF have a high risk of developing pAF (24.4%). 75% of patients with AF do not feel the development of paroxysm. All CHF patients should undergo EchoCG with assessment of LA EF, TDI E med and LA GS to identify a group at risk for the development of AF. Heart rhythm remote monitoring with CardioQVARK® devices can be considered a reliable method for early detection of pAF and timely initiation of anticoagulant therapy in patients with CHF.

show abstract

The role of echocardiography in management of patients with hypertrophic cardiomyopathy (review)

Taradin,

Ignatenko,

Rakitskaya

2023

Medicinskij sovet

Self Cite

View full text Add to dashboard Cite

The presented contains the discussion about the role of echocardiography in management of patients with hypertrophic cardiomyopathy (HCM). The article provides general information about the role of echocardiography in the diagnosis of the disease, clarification of the specific etiology of hypertrophy and differential diagnosis with secondary hypertrophy and phenocopies of HCMP. The features of right and left ventricular (LV) hypertrophy, determination of its predominant localization, phenotype, and conventionally used parameters for assessing myocardial hypertrophy, including the maximum LV wall thickness, LV myocardial mass and LV myocardial mass index, are discussed in detail. Knowledge of phenotypic variants helps to diagnose HCMP, to differentiated approach the management of patients and to choose the optimal treatment strategy. Special attention is paid to the assessment of the structure and function of the mitral valve (MV), the subvalvular apparatus and the phenomenon of systolic anterior motion of the MV responsible for the development of obstruction of the LV outflow tract. The previously existing opinion that cardiac abnormality in HCMP is limited only by hypertrophy of ventricular myocardium has recently undergone changes. Approximately 60% of patients with HCMP have at least one MV anomaly as a direct consequence of genetic mutations. The most common abnormalities that can be detected with echocardiography include elongation of the valvular leaflets and chords, prolapse of the valvular leaflets, hypertrophy, disposition and change in the number of papillary muscles. The importance and significance of assessing LV systolic and diastolic functions using echocardiography is emphasized. The role of transesophageal echocardiography in visualization of hypertrophy features of the MV structure and in the perioperative period during surgical correction of hypertrophied septum and valvular defects is also discussed.

show abstract

Atrial Fibrillation in Hypertrophic Cardiomyopathy

Cited by 3 publications

References 70 publications

Infective Endocarditis in Patients with Hypertrophic Cardiomyopathy

Infective Endocarditis in Patients with Hypertrophic Cardiomyopathy

Determining The Risk of Atrial Fibrillation Paroxysm in Patients With Chronic Heart Failure With Intact and Reduced Ejection Fraction

The role of echocardiography in management of patients with hypertrophic cardiomyopathy (review)

Contact Info

Product

Resources

About